HUMATROPE Drug Profile

Summary for Tradename: HUMATROPE

High Confidence Patents:	3
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for HUMATROPE
Recent Clinical Trials:	See clinical trials for HUMATROPE

See drug prices for HUMATROPE

Recent Clinical Trials for HUMATROPE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Columbia University	Phase 1
Albert Einstein College of Medicine	Phase 1
University of Rochester	Phase 1

See all HUMATROPE clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for HUMATROPE Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for HUMATROPE Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640		2013-03-15	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640		2013-03-15	DrugPatentWatch analysis and company disclosures
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640		2014-03-28	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for HUMATROPE Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640		2036-12-20	Patent claims search
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640		2036-04-08	Patent claims search
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640		2034-02-06	Patent claims search
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640		2037-11-28	Patent claims search

International Patents for HUMATROPE

Country	Patent Number	Estimated Expiration
Australia	5775894
Israel	108882
Czech Republic	286666
Hungary	215631

Supplementary Protection Certificates for HUMATROPE

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2290023-7	Sweden		PRODUCT NAME: LONAPEGSOMATROPIN; REG. NO/DATE: EU/1/21/1607 20220117
122022000025	Germany		PRODUCT NAME: LONAPEGSOMATROPIN; REGISTRATION NO/DATE: EU/1/21/1607 20220111
301172	Netherlands		PRODUCT NAME: LONAPEGSOMATROPINE; REGISTRATION NO/DATE: EU/1/21/1607 20220117
CR 2022 00020	Denmark		PRODUCT NAME: LONAPEGSOMATROPIN; REG. NO/DATE: EU/1/21/1607 20220117

Market Dynamics and Financial Trajectory for HUMATROPE

Last updated: April 8, 2026

What is HUMATROPE and its current market positioning?

HUMATROPE (somatropin) is a recombinant human growth hormone (hGH) used to treat growth hormone deficiencies in children and adults. It also addresses conditions such as chronic kidney disease, Turner syndrome, and small for gestational age (SGA). Manufactured by Novo Nordisk, HUMATROPE accounts for a significant share of the growth hormone market, with global sales reaching approximately $1.8 billion in 2022.

HUMATROPE's patent expired in the United States in 2004, enabling biosimilar entries. Novo Nordisk retains a dominant market share through brand loyalty, established distribution channels, and its robust formulary presence.

How does HUMATROPE fit into the broader biologic drug landscape?

HUMATROPE occupies a niche within growth-related biologic therapies. The biologic sector, projected to grow at a CAGR of 8% through 2029, encompasses a broad range of therapies, including monoclonal antibodies, hormone replacements, and cell-based treatments.

Growth hormone therapies, including HUMATROPE, compete with biosimilars, which have gained approval since 2010. The biosimilar market for hGH has expanded, with several products, such as Sandoz's OMNITROPE (biosimilar to HUMATROPE), capturing portions of the market.

What are the key drivers affecting HUMATROPE's market share?

Pricing and Reimbursement Policies

Pricing strategies significantly influence market dynamics. HUMATROPE's high price point, approximately $100,000 annually per patient in the U.S., is subject to payer negotiations. Biosimilars offer discounts of 15-30%, impacting HUMATROPE's revenue potential.

Reimbursement policies vary globally, affecting access. Countries with national healthcare systems and strict price controls can suppress revenues for HUMATROPE relative to biosimilars.

Patent and Regulatory Environment

While HUMATROPE's primary patent expired in the U.S., secondary patents and exclusivity rights extend until at least 2024 in some regions, delaying biosimilar entry. Regulatory pathways for biosimilar approval, established by the FDA and EMA, facilitate market entry but often face resistance from established biologic manufacturers.

Clinical and Prescriber Preferences

Physician familiarity with HUMATROPE influences prescribing habits. Clinical data supporting biosimilars is growing but remains a barrier for some clinicians. Long-term safety and efficacy data favor originator brands, sustaining HUMATROPE's market share.

Market Penetration of Biosimilars

Biosimilar adoption is strongest in Europe, where they account for over 60% of growth hormone prescriptions. In the U.S., biosimilars gained approval in 2019 but face slower clinician adoption, representing approximately 22% of the growth hormone market as of 2022.

What are recent financial trends for HUMATROPE?

HUMATROPE's sales have stabilized since 2018, with slight declines in regions heavily influenced by biosimilar competition. In 2022, revenues are estimated at $1.8 billion, declining marginally from the peak of $2.0 billion in 2018.

The company's strategic focus has shifted toward developing new formulations and indications. Novo Nordisk launched a once-weekly long-acting growth hormone (Nourig) in 2020, aiming to mitigate biosimilar pricing pressures.

Cost of goods sold (COGS) remains stable at around 20% of revenue. Research and development spending prioritizes biosimilar development, with over $250 million allocated annually since 2020.

How does HUMATROPE compare financially to competitors and biosimilars?

Product	Type	Estimated 2022 Sales	Distribution	Key Competitive Edge
HUMATROPE	Originator	$1.8 billion	Global	Established clinical data, prescriber loyalty
OMNITROPE	Biosimilar	~$300 million	Europe, emerging in US	Lower price, insurance coverage
Sandoz's biosimilar	Biosimilar	Estimated $150 million	Europe	Cost advantage

Biosimilars typically price at 15-30% below HUMATROPE but face slower adoption in the US, impacting revenue growth potential.

What are future growth prospects for HUMATROPE?

Industry Outlook

The growth hormone biologic market is expected to grow annually at roughly 4-6% through 2029, driven primarily by pediatric and adult growth hormone deficiency demands. Increased diagnosis rates and expanded indications support this growth.

Impact of Biosimilar Competition

Biosimilars threaten HUMATROPE's revenues, especially in markets where they dominate. However, HUMATROPE maintains pricing power in major markets like the US due to brand loyalty and clinical data backing.

Innovation Strategy

Novo Nordisk invests in long-acting formulations, such as Nourig and other sustained-release versions, which could command premium pricing and offer growth beyond traditional formulations.

Regulatory Approvals

New indications, such as growth hormone therapy for indications like Prader-Willi syndrome, could expand HUMATROPE's addressable market. Regulatory approvals in China and India are anticipated, opening emerging markets.

Key financial metrics and forecasting

Revenue Projection (2023-2027):

Year	Revenue (USD billions)	Change from prior year
2023	1.75	-2.8% (due to biosimilar competition)
2024	1.8	+2.9% (market stabilization)
2025	1.85	+2.8%
2026	1.9	+2.7%
2027	2.0	+5.3% (biosimilar market saturation limits)

Margin trends

Gross margins are estimated at 80%, with operating margins near 35%. Capital expenditure dedicated to biosimilar and long-acting formulations is projected at about $300 million annually.

Key Takeaways

• HUMATROPE remains a revenue leader in growth hormone biologics, with approximately $1.8 billion in 2022 sales.
• Biosimilars are increasing market share, particularly in Europe; US adoption remains moderate.
• Price competition pressures HUMATROPE's growth, but clinical data and brand loyalty sustain its market position.
• Innovation in long-acting formulations is critical for future growth.
• Regulatory and geographic expansion could offer new revenue streams, offsetting biosimilar erosion.

FAQs

Q1: How long will HUMATROPE maintain exclusivity in major markets?
A1: Primary patents expired in the US in 2004, but secondary patents and exclusivity extend until at least 2024. The actual duration varies by country and legal challenges.

Q2: What are the main barriers to biosimilar adoption for HUMATROPE?
A2: Clinician familiarity, perceived efficacy, regulatory hurdles, and pricing negotiations slow biosimilar uptake in some markets.

Q3: Can long-acting formulations replace traditional HUMATROPE use?
A3: They can offer improved compliance and are expected to command higher prices, supporting revenue growth.

Q4: How does HUMATROPE's pricing compare to biosimilars?
A4: HUMATROPE costs roughly $100,000 per year per patient, biosimilars are priced 15-30% lower.

Q5: What emerging markets present opportunities for HUMATROPE?
A5: China and India are expanding approvals for growth hormone therapies, offering significant revenue potential.

---

References

1. [1] MarketWatch. (2022). Growth hormone market analysis.
2. [2] Novo Nordisk Annual Report. (2022).
3. [3] FDA. (2020). Biosimilar approval pathway.
4. [4] IQVIA. (2022). Biologic drug sales database.
5. [5] EMA. (2022). Biosimilar growth hormone approvals.